

Article

Design, Synthesis, and Biological Activity of New Triazole and Nitro-Triazole Derivatives as Antifungal Agents

Hossein Sadeghpour ¹, Soghra Khabnadideh ¹, Kamiar Zomorodian ², Keyvan Pakshir ², Khadijeh Hoseinpour ¹, Nabiollah Javid ¹, Ehsan Faghieh-Mirzaei ³ and Zahra Rezaei ^{1,*}

¹ Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 7146864685, Iran; sadeghpurh@sums.ac.ir (H.S.); khabns@sums.ac.ir (S.K.); hoseinpour65k@gmail.com (K.H.); javidn@yahoo.com (N.J.)

² Department of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran; zomorodian@sums.ac.ir (K.Z.); pakshirk@sums.ac.ir (K.P.)

³ Department of Medicinal Chemistry, School of Pharmacy, Kerman University of Medical Sciences, Kerman 7616911319, Iran; ehsancontact@kmu.ac.ir

* Correspondence: rezaeiza@sums.ac.ir; Tel.: +98-713-242-5305; Fax: +98-713-242-4126

Received: 17 June; Accepted: 7 July; Published: 10 July 2017

Abstract: In this study two series of fluconazole derivatives bearing nitrotriazole (series A) or piperazine ethanol (series B) side chain were designed and synthesized and then docked in the active site of lanosterol 14 α -demethylase enzyme (1EA1) using the Autodock 4.2 program (The scripps research institute, La Jolla, CA, USA). The structures of synthesized compound were confirmed by various methods including elemental and spectral (NMR, CHN, and Mass) analyses. Then antifungal activities of the synthesized compound were tested against several natural and clinical strains of fungi using a broth microdilution assay against several standard and clinical fungi. Nitrotriazole derivatives showed excellent and desirable antifungal activity against most of the tested fungi. Among the synthesized compounds, **5a–d** and **5g**, possessing nitrotriazole moiety, showed maximum antifungal activity, in particular against several fluconazole-resistant fungi.

Keywords: fluconazole; synthesis; antifungal; lanosterol 14 α -demethylase; docking; nitrotriazole

1. Introduction

Fungal infections have become a serious clinical challenge in recent years due to clinical issues such as cancer chemotherapy, transplantation, HIV infections, and the use of immunosuppressive agents [1–4]. Among the antifungal agents, azoles were used widely in treatment of fungal infections, which inhibit the lanosterol 14 α -demethylase (CYP51) to prevent ergosterol biosynthesis from lanosterol in yeast and fungi. The selective inhibition of CYP51 causes depletion of ergosterol and the accumulation of lanosterol and other 14 α -methyl sterols, resulting in the growth inhibition of fungal cells [5]. Fluconazole, a triazole derivative, is a first-line antifungal agent with low toxicity and high antifungal activity. Some species of fungi are resistant against fluconazole, and this is now becoming a serious clinical problem [5]. In order to enhance the antifungal activity or reduce antifungal resistance, many fluconazole derivatives were synthesized containing other heterocycles instead of 1,2,4-triazole [6–13], such as tetrazole [7], indole [8], indoline, benzimidazole [9], imidazole or 1,2,3-triazol [12,13]. Voriconazole and ravuconazole are two clinically important antifungal triazoles in which the second ring is replaced by fluoropyrimidine and thiazole derivatives, respectively [14]. The introduction of halogenated quinazoline instead of a triazole ring in the fluconazole structure results in albaconazole with higher in vitro activity in comparison to fluconazole [6]. Antifungal activity improved in the amide derivatives containing a pyrrolo-pyridine portion [6]. The triazole

containing agents can show various biological activities other than antifungal ones [15,16]. Among them, the cytotoxic effects can lead us to new antineoplastic hits [17]. On the other hand some studies indicated that triazole-functionalized multi-walled carbon nanotubes can be used to remove metal impurities from water [18] or can be used as an effective antibiofouling agents [19].

There are a few reports about the antifungal activity of nitroimidazole or nitropyrazole [20]. To our knowledge, there is no report about the antifungal activities of nitrotriazoles. On the other hand introducing a piperazine ring to the azole structure leads to better antifungal activity and fewer toxicities [7,21]. Itraconazole and posaconazole with a piperazine ring in their structures are the best examples [6]. Fluconazole derivatives with substituted phenoxypropyl piperazine side chains or a piperazinyl phenyl side chain showed in vitro antifungal activity against several pathogenic fungi [10,11,21,22].


Docking simulation is a key tool in structural molecular biology and computer-assisted drug design (CAAD) to predict the “best-fit” orientation of ligands against active sites in antifungal discovery [11,23,24].

In this study, two series of fluconazole derivatives bearing a nitrotriazole or piperazine ethanol side chain were designed and then docked in the active site of 14 α -demethylase enzyme (1EA1) using the Autodock 4.2 program. Designed compounds with the least final docking energy (FDE) values were synthesized and their antifungal activities were tested against several yeasts and filamentous fungi.

2. Results and Discussion

2.1. Chemistry

In this study, two series of compounds, series A (**5a–e**), which contain nitrotriazole, and series B (**5f–j**), with piperazine moiety in their structures, were synthesized (Scheme 1). The synthesis routes are based on the previous reports in the literatures [8,10–13,21,25] with few modifications. Briefly, the key oxirane intermediate (compound **4**) was synthesized using trimethylsulfoxonium iodide (TMSI) and sodium hydroxide in dichloromethane/toluene in the presence of a phase transfer catalyst, tetraethylammonium bromide (TEAB). In the final step, 3-Nitro-1,2,4-triazole or 2-(1-piperazinyl) ethanol was allowed to react with epoxy intermediate **4**. 3-Nitro-1,2,4-triazole or 2-(1-piperazinyl) ethanol could be added to compound **2** or epoxy intermediate **4**. Based on our experiences the goal products **5a–j** were obtained in higher yields when 3-nitro-1*H*-1,2,4-triazole or 2-(1-piperazinyl) ethanol were applied in the final step.



Scheme 1. Synthesis of the new fluconazole compounds; conditions: (a) AlCl₃, 1,2-dichloroethane, chloroacetyl chloride, 25–30 °C; (b) 1*H*-1,2,4-triazole, NaHCO₃, toluene, reflux; (c) trimethylsulfoxonium iodide (TMSI), NaOH, tetraethylammonium bromide (TEAB), dichloromethane, toluene, 60 °C; (d) EtOH, Et₃N, 3-nitro-1,2,4 triazol, 80 °C; (e) EtOH, Et₃N, 2-(piperazin-1-yl) ethanol, 80 °C.

2.2. Biological Activity

The antifungal activities (MICs) of the synthesized compounds were investigated against several standard and clinically isolated fungi using the serial microdilution assay. Fluconazole was used as the positive control (Tables 1 and 2). The MICs showed that yeasts are more sensitive than filamentous fungi to the synthesized compounds. Antifungal activity of fluconazole against tested fungi showed that fluconazole has also minimal activity on filamentous ones. These findings suggested that the mechanism of action of the new compounds may be similar to fluconazole. More interestingly, the clinically isolated microorganisms were more sensitive than standard species (Table 1). The results showed that all the synthesized derivatives except **5i**, **5j** and **5h** exhibited moderate to high in vitro antifungal activities. Compounds **5a**, **5b** and **5g**, which bear 2, 4-dichlorophenyl or 2,4-difluorophenyl group, had better antifungal activity against most tested fungal strains (Tables 1 and 2). Compound **5b** had the most antifungal activity against all fungal strains except *Aspergillus* sp. As shown in Table 1 compounds **5b**, **5f**, **5g** and **5i** had antifungal activity against fluconazole-resistant fungi (*C. krusei* (ATCC 6258)). **5b** also showed antifungal activity more than fluconazole on some standard and clinically isolated strains such as *C. albicans* (CBS 5982), *C. albicans* (CBS 1905), and *C. krusei* (ATCC6258). The most sensitive fungal strains to the synthesized compounds were *C. dubliniensis* (CBS 8501), *C. dubliniensis* (CBS 7987), *C. dubliniensis* (CBS 7988), *C. albicans* (CBS 1912), and *C. albicans* (CBS 1905), whereas the *Aspergillus* species were not sensitive to any of our compounds.

Table 1. Antifungal activities of **5a–5j** against Yeasts (MICs, µg/mL).

Tested Fungi	Compounds										Fluconazole
	5a	5b	5c	5d	5e	5f	5g	5h	5i	5j	
<i>C. glabrata</i> (CBS 863)	128	16	G	G	G	256	8	64	G	G	4
<i>C. dubliniensis</i> (CBS 8501)	4	0.5	128	16	G	G	32	G	G	G	0.5
<i>C. dubliniensis</i> (CBS 7987)	2	0.5	32	4	64	G	1	G	G	G	0.5
<i>C. dubliniensis</i> (CBS 7988)	2	0.5	8	2	32	G	32	G	G	G	0.5
<i>C. albicans</i> (CBS 5982)	256	128	256	256	G	G	2	G	G	G	256
<i>C. glabrata</i> (CBS 6144)	128	32	G	G	G	G	4	G	G	G	4
<i>C. albicans</i> (CBS 2730)	16	2	256	32	G	G	64	G	G	G	<0.5
<i>C. albicans</i> (CBS 562)	16	1	128	32	G	G	16	G	G	G	<0.5
<i>C. albicans</i> (CBS 1912)	8	0.5	128	16	256	16	2	G	G	G	0.25
<i>C. glabrata</i> (CBS 2192)	128	32	G	G	G	32	0.5	G	G	G	8
<i>C. glabrata</i> (CBS 2175)	128	16	G	G	G	32	1	G	G	G	4
<i>C. dubliniensis</i> (CBS 8500)	8	0.5	64	8	256	G	128	G	G	G	0.25
<i>C. albicans</i> (CBS 1905)	4	<0.5	64	8	G	G	0.5	G	128	G	0.5
<i>C. tropicalis</i> (ATCC750)	16	4	G	64	G	G	4	NT	G	G	2
<i>C. arapsilosis</i> (ATCC4344)	16	2	G	128	G	G	8	NT	64	G	0.5
<i>C. krusei</i> (ATCC6258)	G	128	G	G	G	64	1	NT	64	G	G
<i>Cryptococcus neoformans</i> (ATCC9011)	32	2	256	64	256	G	8	NT	G	G	1
<i>C. albicans</i> *	4	0.5	128	16	256	64	2	256	256	256	1
<i>C. glabrata</i> *	NT	NT	NT	NT	NT	128	8	256	256	256	0.25
<i>C. dubliniensis</i> *	16	1	256	256	256	16	1	256	128	256	0.5

G: growth, NT: not tested, *: Clinical isolated Yeasts; MICs: Minimal Inhibitory Concentrations.

Table 2. Antifungal activities of **5a–5j** against filamentous fungi (MIC, µg/mL).


Fungi	Compounds										Fluconazole
	5a	5b	5c	5d	5e	5f	5g	5h	5i	5j	
<i>Microsporum gypseum</i>	64	4	G	G	G	256	64	256	G	G	8
<i>Epidermophyton floccosum</i>	128	64	G	G	G	64	32	64	G	G	G
<i>Trichophyton mentagrophytes</i>	128	128	G	G	G	64	G	G	G	G	G
<i>Aspergillus fumigatus</i>	128	G	G	G	G	G	G	G	G	G	G
<i>Aspergillus fumigatus</i>	128	G	G	G	G	G	G	G	G	G	G
<i>Aspergillus fumigatus</i>	G	G	G	G	G	G	G	G	G	G	G
<i>Aspergillus clavatus</i>	G	G	G	G	G	G	G	G	G	G	G
<i>Aspergillus flavus</i>	G	G	G	G	G	G	G	G	G	G	G

G: growth.

2.3. Docking

Fluconazole and all of the synthesized compounds **5a–j** were docked into the active site of lanosterol 14 α -demethylase enzyme (1EA1) and the FDE was calculated (Table 3). As shown in Table 2, all compounds had more negative FDE values than fluconazole, and compound **5b** had the best FDE value. **5b** had the highest LogP (Log Partition Coefficient) and the best FDE as well as overall highest antifungal activity. The results revealed some correlation between these parameters and antifungal effects (Tables 1, 2 and 3). Generally, the synthesized compounds in series A had more negative FDE and better antifungal activities compared to series B. This may be attributed to the better electrostatic interaction of NO₂ moiety of these compounds with Fe²⁺ in the heme molecule of 14 α -demethylase. In addition, the compounds in series A had higher log P compared to series B. As more lipophilic agents demonstrated better antifungal activity, it can be concluded that lipophilicity can enhance the penetration of these compounds to fungal cells.

Table 3. Docking results for compounds **5a–j** into the active site of 14 α -demethylase enzyme (1EA1).



Compounds	Final Docked Energy (Kcal/mol)	LogP	R1	R2	R3
5a	−10.82	0.73	F	F	3-nitro-1,2,4-triazol
5b	−11.98	1.48	Cl	Cl	3-nitro-1,2,4-triazol
5c	−11.91	0.59	F	H	3-nitro-1,2,4-triazol
5d	−11.83	0.97	Cl	H	3-nitro-1,2,4-triazol
5e	−11.14	0.45	H	H	3-nitro-1,2,4-triazol
5f	−7.17	0.27	F	F	2-(piperazin-1-yl)ethanol
5g	−8.26	1.31	Cl	Cl	2-(piperazin-1-yl)ethanol
5h	−7.36	0.41	F	H	2-(piperazin-1-yl)ethanol
5i	−8.03	0.79	Cl	H	2-(piperazin-1-yl)ethanol
5j	−7.25	0.28	H	H	2-(piperazin-1-yl)ethanol
Fluconazole	−6.74	0.99	F	F	1H-1,2,4-triazole

2.4. Structure Activity Relationship

The replacement of one of the triazole rings with nitrotriazole leads to increased antifungal activity for several synthesized compound in compare with fluconazole. The binding model of compound **5b** and **5g** with 14 α -demethylase is illustrated in Figure 1. As shown in Figure 1, the molecules are well accommodated in the active pocket. The nitrotriazole derivatives, series A, had the better electrostatic interaction with the heme core of enzyme in comparison with piperazine derivatives, series B. The iron-N distance in the active site of 14 α -demethylase for **5b** and **5g** (0.124 nm vs. 0.243 nm) may be responsible for this interaction leading to better enzyme inhibition and antifungal activity. These findings indicated that the nitro group may be able to provide better interaction in the active site of 14 α -demethylase in comparison with N₄ of triazole (Figure 1). Among series A, compound **5b** showed the best antifungal effect; in series B, **5g** had the most antifungal effect against several tested microorganisms. These two compounds had two chlorine in their structures. The elimination of halogens from compounds to form compounds **5e** and **5j** reduced antifungal activity. This can be attributed to the better hydrophobic interaction of electron-poor phenyl group with a phenyl ring of Phe83, Phe78, and Phe255, which surround the ligand in the active site (Figure 1). On this basis the replacement of chlorine with fluorine or hydrogen will result in less antifungal effect and FDE (Tables 1 and 2).




Figure 1. Visualizing the active site in the presence of ligands: left (**5b**), right (**5g**).

3. Materials and Methods

3.1. Chemistry

All reagents and solvents were purchased from commercial suppliers and used without further purification. Melting points were determined by using an Electrothermal 9100 digital melting point apparatus (Electrothermal, Essex, UK). The reaction progress and purity of the synthesized compounds were checked on Merck aluminum plates precoated with silica gel 60 F-254 (Merck KGaA, Darmstadt, Germany). UV radiation and/or iodine were used as the visualizing agents. Silica gel column chromatography was performed with Silica gel 60G (Merck KGaA, Darmstadt, Germany). Spectroscopic data were recorded on the following instruments: ^1H -NMR spectra was recorded on a Bruker 500 spectrometer with TMS (tetramethylsilane) (Germany) as internal standard and CDCl_3 as the solvent and ^{13}C -NMR spectra was recorded on a Bruker 300 spectrometer (Germany). Chemical shifts (δ values) and coupling constants (J values) are given in ppm and Hz, respectively. Signal multiplicities are represented by s (singlet), d (doublet), t (triplet), dd (double of doublet), dt (double of triplet), m (multiplet), and brs (broad singlet). Mass spectra were recorded on a Hewlett-Packard GC-MS (Agilent, Santa Clara, CA, USA). The CHN analysis were done by ECS 4010 (Caltech Company, Firenze, Italy).

3.1.1. General Procedure for the Synthesis of 2-chloro-1-(2,4-disubstituted phenyl) Ethanone (**2a–e**)

Disubstituted benzenes **1a–e** (50 mmol) and anhydrous aluminum chloride (60 mmol, 7.98 g) were stirred in 60 mL dichloroethane at 30 °C for 30 min. The mixture was then cooled to 0 °C in an ice bath and was charged dropwise with chloroacetyl chloride solution (54 mmol, 6.21 g) while stirring during 30 min. Stirring was continued for further 30 min keeping the reaction mixture at 0–10 °C. Then the mixture was warmed to room temperature and stirred for 24 h. Afterward the reaction was quenched by the addition of hydrochloric acid (1 M) and the mixture was extracted with dichloroethane in 0–5 °C. The combined organic layers were washed with 2 × 20 mL saturated NaHCO_3 and then with cold water and brine, dried over anhydrous sodium sulfate (Na_2SO_4) and concentrated in a vacuum. The crude product was purified by recrystallization from n-hexane, affording **2a–e**.

3.1.2. General Procedure for the Synthesis of 1-(2,4-disubstituted phenyl)-2-(1H-1,2,4-triazol-1-yl) Ethanone (**3a–e**)

A flask equipped with a reflux condenser was charged with a mixture of 2-chloro-1-(2,4-disubstituted phenyl) ethanone (**2a–e**) (40 mmol) and 1,2,4-triazole (40 mmol, 3.31g) which refluxed in 40 mL toluene in the presence of sodium bicarbonate (48 mmol, 4.04 g) for 24 h. Then the reaction

mixture was poured into crushed ice and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in a vacuum. The compounds **3a–e** crystallized from diethyl ether.

3.1.3. General Procedure for the Synthesis of 1-((2-(2,4-disubstituted phenyl)oxiran-2-yl)methyl)-1*H*-1,2,4-triazole (**4a–e**)

A mixture of 1-(2,4-disubstituted phenyl)-2-(1*H*-1,2,4-triazol-1-yl) ethanone (**3a–e**) in 15 mL dichloromethane, trimethylsulfoxonium iodide, TMSI, (18.03 mmol, 3.97 g) and 30 mL toluene was charged by sodium hydroxide solution (20%, 3.7 mL) and tetraethyl ammonium bromide TEAB (3 mmol, 0.63 g). The reaction mixture was heated for 7 h at 60 °C. Progress of the reaction was monitored by TLC. After completion of the reaction, the product was diluted with water and extracted with ethyl acetate (2 × 40 mL). The organic layer was washed and dried over anhydrous sodium sulfate and concentrated. The crude products were purified by a preparative thin layer chromatography using chloroform and methanol (94:4) to get the brown oily products (**4a–e**).

3.1.4. General Procedure for the Synthesis of 2-(2,4-disubstituted phenyl)-1-(3-nitro-1*H*-1,2,4-triazol-1-yl)-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ol (**5a–e**, series A)

Twenty mL of solution of 1-((2-(2,4-disubstituted phenyl)oxiran-2-yl) methyl)-1*H*-1,2,4-triazole (**4a–e**) (3 mmol) and triethylamine (1.8–2.9 mL) in absolute ethanol was added to 3-nitro-1,2,4-triazole (4 mmol, 0.456 g) and refluxed for 15–24 h. TLC monitoring was used to control reaction progress. The mixture was filtered, concentrated and diluted with 30 mL water. Then filtrate was extracted with ethyl acetate (3 × 80 mL). The combined organic layers were washed with water and then with brine, dried over anhydrous sodium sulfate and concentrated in a vacuum. The crude products were crystallized from various solvents to gain the products **5a–e** (series A).

3.1.5. General Procedure for the Synthesis of 2-(2,4-disubstituted phenyl)-1-(3-nitro-1*H*-1,2,4-triazol-1-yl)-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ol (**5f–j**, series B)

Twenty mL of solution of 1-((2-(2,4-disubstituted phenyl)oxiran-2-yl) methyl)-1*H*-1,2,4-triazole (**4a–e**) (3 mmol) and triethylamine (1.8–2.9 mL) in absolute ethanol was added to 4 mmol of 2-(1-pyrazolyl) ethanol and refluxed for 15–24 h. TLC monitoring was used to control reaction progress. The mixture was filtered, concentrated and diluted with 30 mL water. Then filtrate was extracted with ethyl acetate (3 × 80 mL). The combined organic layers were washed with water and then with brine, dried over anhydrous sodium sulfate and concentrated in a vacuum. The crude products were crystallized from various solvents or purified by preparative thin layer chromatography in a solvent system containing chloroform and methanol (88:12) to get the brown oily products **5f–j** (series B).

2-(2,4-Difluorophenyl)-1-(3-nitro-1*H*-1,2,4-triazol-1-yl)-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ol (5a**).** pale yellow solid (34% yield, m.p.: 159–161 °C). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.19 (s, 1H, nitrotriazole), 8.02 (s, 1H, triazole), 7.69 (s, 1H, triazole), 7.17 (td, *J* = 8.5 Hz, *J* = 6.45 Hz, 1H, Ar-H), 6.76 (m, 1H, Ar-H), 6.64 (dt, *J* = 8.5 Hz, *J* = 2.3 Hz, 1H, Ar-H), 6.15 (s, 1H, OH), 4.72 (d, 1H, *J* = 14.5 Hz, CH₂), 4.63 (d, *J* = 12.5 Hz, 2H, CH₂), 4.54 (d, *J* = 14.5 Hz 1H, CH₂). ¹³C-NMR (75 MHz, CDCl₃): δ = 152.42 (C-NO₂), 145.89 (C₃ triazole), 144.35 (C-3 triazole, C-5 nitrotriazole), 130.08 (2,4-F₂Ph C-1), 112.82 (2,4-F₂Ph C-5), 104.94 (2,4-F₂Ph C-3), 74.97 (C-OH), 56.87 (CH₂-nitrotriazole), 54.03 (CH₂-triazole). MS (*m/z*, %): 352 (M⁺ + 1, 16), 269 (51), 224 (100), 132 (11), 155 (29), 141 (87), 127 (100), 113 (19), 101 (11), 83 (100), 55 (58), 41 (11). Anal. Calcd. for C₁₃H₁₁F₂N₇O₃ (351.3): C, 44.45; H, 3.16; F, 10.82; N, 27.91; O, 13.66. Found: C, 44.25; H, 3.32; N, 27.84.

2-(2,4-Dichlorophenyl)-1-(3-nitro-1*H*-1,2,4-triazol-1-yl)-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ol (5b**).** White solid (35% yield, m.p.: 168–170 °C). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.36 (s, 1H, nitrotriazole), 8.10 (s, 1H, triazole), 7.89 (s, 1H, triazole), 7.58 (d, 1H, *J* = 8.6 Hz, Ar-H), 7.43 (d, 1H, *J* = 1.9 Hz, Ar H), 7.21 (dd, 1H, *J* = 8.6 Hz, *J* = 1.9 Hz, Ar-H), 5.82 (brs, 1H, OH), 5.56 (d, 1H, *J* = 14.4 Hz, CH₂), 5.10 (d, 1H, *J* = 14.4 Hz, CH₂), 4.82 (d, 1H, *J* = 14.4 Hz, CH₂), 4.39 (d, 1H, *J* = 14.4 Hz, CH₂). ¹³C-NMR (75 MHz, CDCl₃): δ = 152.32 (C-NO₂), 146.99 (C-3 triazole), 144.18 (C-3 triazole, C-5 nitrotriazole), 136.21 (2,4-

Cl₂ Ph C-1), 133.58 (2,4-Cl₂ Ph C-4), 131.05 (2,4-Cl₂ Ph C-2), 130.50 (2,4-Cl₂ Ph C-3), 130.00 (2,4-Cl₂ Ph C-6), 128.23 (2,4-Cl₂ Ph C-5), 76.27 (C-OH), 55.5 (CH₂-nitrotriazole), 52.57 (CH₂-triazole). MS (*m/z*, %): 384 (M⁺, 10), 348 (8), 301 (10), 256 (33), 214 (100), 187 (11), 173 (25), 158 (43), 145 (11), 123 (13), 109 (16), 82 (85), 55 (45), 42 (8). Anal. Calcd. for C₁₃H₁₁Cl₂N₇O₃ (384.2): C, 40.64; H, 2.89; Cl, 18.46; N, 25.52; O, 12.49. Found: C, 40.24; H, 2.9; N, 25.32.

2-(4-Fluorophenyl)-1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5c**). White crystalline solid (35% yield, m.p.: 181–182 °C). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.26 (s, 1H, nitrotriazole), 7.93 (s, 2H, triazole), 7.29–7.732 (m, 2H, Ar-H), 7.04–7.08 (m, 2H, Ar-H), 5.52 (s, 1H, OH), 4.71 (d, 1H, *J* = 14.2 Hz, CH₂), 4.64 (d, 1H, *J* = 14.4 Hz, CH₂), 4.57 (d, 1H, *J* = 14.4 Hz, CH₂), 4.40 (d, 1H, *J* = 14.2 Hz, CH₂). ¹³C-NMR (75 MHz, CDCl₃): δ = 152.50 (C-NO₂), 146.78 (C-3 triazole), 144.61 (C-3 triazole, C-5 nitrotriazole), 126.63 (4-FPh C-2, C-6), 116.11 (4-FPh C-3, C-5), 76.57 (C-OH), 58.46 (CH₂-nitrotriazole), 55.25 (CH₂-triazole). MS (*m/z*, %): 334 (M⁺ + 1, 16), 251 (55), 206 (100), 164 (66), 137 (41), 123 (82), 109 (100), 95 (55), 83 (100), 55 (49), 42 (9). Anal. Calcd. for C₁₃H₁₂FN₇O₃ (333.3): C, 46.85; H, 3.63; F, 5.70; N, 29.42; O, 14.40. Found: C, 46.98; H, 3.91; N, 28.95.

2-(4-Chlorophenyl)-1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5d**). Pale yellow solid (35% yield, m.p.: 147 °C). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.17 (s, 1H, nitrotriazole), 7.92 (s, 1H, triazole), 7.71 (s, 1H, triazole), 7.22–7.29 (m, 4H, Ar-H), 6.08 (brs, 1H, OH), 4.62 (d, 1H, *J* = 14.4 Hz, CH₂), 4.58 (d, 1H, *J* = 14.3 Hz, CH₂), 4.49 (d, 1H, *J* = 14.4 Hz, CH₂), 4.40 (d, 1H, *J* = 14.3 Hz, CH₂). ¹³C-NMR (75 MHz, CDCl₃): δ = 152.51 (C-NO₂), 147.04 (C-3 triazole), 144.62 (C-3 triazole, C-5 nitrotriazole), 136.96 (4Cl-Ph C-4), 135.20 (4Cl-Ph C-3, C-5), 129.42 (4Cl-Ph C-2, C-6), 126.20 (4Cl-Ph C-1), 75.59 (C-OH), 58.32 (CH₂-nitrotriazole), 55.17 (CH₂-triazole). MS (*m/z*, %): 350 (M⁺ + 1, 18), 267 (34), 222 (100), 180 (61), 153 (23), 139 (55), 125 (97), 111 (31), 83 (100), 55 (43), 42 (8). Anal. Calcd. for C₁₃H₁₂ClN₇O₃ (349.7): C, 44.65; H, 3.46; Cl, 10.14; N, 28.03; O, 13.72. Found: C, 44.15; H, 3.21; N, 27.91.

1-(3-Nitro-1H-1,2,4-triazol-1-yl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5e**). White solid (36% yield, m.p.: 160–163 °C). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.22 (s, 1H, nitrotriazole), 7.94 (s, 1H, triazole), 7.92 (s, 1H, triazole), 7.31–7.37 (m, 5H, Ar-H), 5.45 (brs, 1H, OH), 4.74 (d, 1H, *J* = 14.2 Hz, CH₂), 4.68 (d, 1H, *J* = 14.4 Hz, CH₂), 4.60 (d, 1H, *J* = 14.4 Hz, CH₂), 4.43 (d, 1H, *J* = 14.4 Hz, CH₂). ¹³C-NMR (75 MHz, CDCl₃): δ = 152.10 (C-NO₂), 145.50 (C-3 triazole), 144.38 (C-3 triazole, C-5 nitrotriazole), 137.92 (Ph C-1), 128.92 (Ph C-3, C-5), 128.70 (Ph C-4), 127.40 (Ph C-2, C-6), 75.52 (C-OH), 58.25 (CH₂-nitrotriazole), 55.18 (CH₂-triazole). MS (*m/z*, %): 316 (M⁺ + 1, 33), 233 (57), 188 (100), 146 (100), 119 (49), 105 (74), 91 (100), 83 (100), 77 (71), 66 (20), 55 (43), 41 (8), 30 (20). Anal. Calcd. for C₁₃H₁₃N₇O₃ (315.3): C, 49.52; H, 4.16; N, 31.10; O, 15.22. Found: C, 49.65; H, 4.32; N, 31.35.

2-(2,4-Difluorophenyl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5f**). Brown oil (55% yield). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.09 (s, 1H, triazole), 7.72 (s, 1H, triazole), 7.46–7.49 (m, 1H, Ar-H), 6.73–6.77 (m, 2H, Ar-H), 4.47–4.50 (d, 1H, *J* = 14.3 Hz, CH₂-triazole), 4.43–4.46 (d, 1H, *J* = 14.3 Hz, CH₂-triazole), 3.50–3.52 (m, 2H, CH₂-OH), 3.00–3.03 (d, 1H, *J* = 14.1 Hz, CH₂-piperazine), 2.60–2.63 (d, 1H, *J* = 14.1 Hz, CH₂-piperazine), 2.41–2.43 (m, 2H, piperazine-CH₂), 2.33–2.44 (m, 8H, piperazine), 1.16–1.18 (brs, 1H, OH). MS (*m/z*, %): 368 (M⁺ + 1, 17.9), 336 (0.7), 299 (1.4), 2.85 (4.3), 143 (100), 127 (5), 113 (3.6), 100 (14.3), 82 (3.6), 70 (20.7), 56 (5.7). Anal. Calcd. for C₁₇H₂₃F₂N₅O₂ (367.4): C, 55.58; H, 6.31; F, 10.34; N, 19.06; O, 8.71. Found: C, 55.67; H, 6.25; N, 18.96.

2-(2,4-Dichlorophenyl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5g**). Brown oil (58% yield). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.14 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.70–7.72 (d, 1H, *J* = 8.5 Hz, Ar-H), 7.36–7.37 (d, 1H, *J* = 2.1 Hz, Ar-H), 7.17–7.19 (dd, 1H, *J* = 2.1 Hz, Ar-H), 4.71–4.74 (d, 1H, *J* = 14.25 Hz, CH₂-triazole), 4.67–4.70 (d, 1H, *J* = 14.25 Hz, CH₂-triazole), 3.54 (m, 2H, CH₂-OH), 3.44–3.47 (d, 1H, *J* = 13.75 Hz, CH₂-piperazine), 2.67–2.70 (d, 1H, *J* = 13.75 Hz, CH₂-piperazine), 2.46–2.47 (dd, 2H, *J* = 4.5 Hz, piperazine-CH₂), 2.33–2.45 (m, 8H, piperazine), 1.20–1.27 (brs, 1H, OH). MS (*m/z*, %): 400 (M⁺, 8.3), 317 (3.3), 159 (2.5), 143 (100), 128 (1.7), 113 (3.3), 100 (15), 82 (3.3), 70 (17.5), 56 (7.5). Anal. Calcd. for C₁₇H₂₃Cl₂N₅O₂ (400.3): C, 51.01; H, 5.79; Cl, 17.71; N, 17.50; O, 7.99. Found C, 50.97; H, 5.66; N, 17.52.

2-(4-Fluorophenyl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5h**). Brown oil (42% yield). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.01 (s, 1H, triazole), 7.73 (s, 1H, triazole), 7.28–7.31 (m, 2H, Ar-H), 6.90–6.93 (t, 2H, *J* = 8.5 Hz, Ar-H), 4.29–4.32 (d, 1H, *J* = 14 Hz, CH₂-triazole), 4.21–4.24 (d, 1H, *J* = 14 Hz, CH₂-triazole), 3.47 (t, 2H, *J* = 5 Hz, CH₂-OH), 2.80–2.83 (d, 1H, *J* = 13.25 Hz, CH₂-piperazine), 2.55–2.58 (d, 1H, *J* = 13.25 Hz, CH₂-piperazine), 2.36–2.38 (m, 2H, piperazine-CH₂), 2.21–2.28 (m, 8H, piperazine), 1.10 (brs, 1H, OH). MS (*m/z*, %): 350 (*M*⁺ + 1, 25), 281 (2.14), 267 (3.9), 143 (100), 128 (1.8), 109 (3.9), 100 (12.9), 91 (0.7), 82 (2.1), 70 (17.8), 56 (5.7). Anal. Calcd. for C₁₇H₂₄FN₅O₂ (349.4): C, 58.44; H, 6.92; F, 5.44; N, 20.04; O, 9.16. Found C, 58.23; H, 6.74; N, 20.27.

2-(4-chlorophenyl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5i**). Brown oil (46% yield). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.06 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.26–7.33 (dd, *J* = 9 Hz, 4H, phenyl), 4.32–4.35 (d, 1H, *J* = 14 Hz, -CH₂-triazole), 4.24–4.27 (d, 1H, *J* = 14 Hz, -CH₂-triazole), 3.52 (m, 2H, CH₂-OH), 2.86–2.89 (d, 1H, *J* = 13.5 Hz, -CH₂-piperazine), 2.62–2.65 (d, 1H, *J* = 13.5 Hz, -CH₂-piperazine), 2.42–2.44 (dd, 2H, *J* = 3.9 Hz, piperazine-CH₂), 2.26–2.34 (m, 8H, piperazine), 1.22–1.30 (brs, 1H, OH). MS (*m/z*, %): 366 (*M*⁺, 18.9), 297 (1.3), 283 (2.5), 143 (100), 125 (3.1), 113 (3.1), 100 (11.9), 91 (0.6), 82 (2.5), 70 (16.4), 56 (6.3). Anal. Calcd. for C₁₇H₂₄ClN₅O₂ (365.8): C, 55.81; H, 6.61; Cl, 9.69; N, 19.14; O, 8.75. Found C, 55.62; H, 6.73; N, 19.03.

1-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ol (**5j**). Brown oil (38% yield). ¹H-NMR (500 MHz, CDCl₃, ppm): 8.02 (s, 1H, triazole), 7.78 (s, 1H, triazole), 7.21–7.38 (m, 5H, phenyl), 4.35–4.38 (d, 1H, *J* = 14.25 Hz, -CH₂-triazole), 4.25–4.28 (d, 1H, *J* = 14.25 Hz, -CH₂-triazole), 3.50 (m, 2H, -CH₂-OH), 2.59–2.91 (dd, 2H, *J* = 13 Hz, CH₂-piperazine), 2.40–2.41 (m, 2H, piperazine-CH₂), 2.23–2.31 (m, 8H, piperazine), 1.21–1.24 (brs, 1H, OH). MS (*m/z*, %): 332 (*M*⁺ + 1, 10.7), 249 (6.40), 188 (3.6), 143 (100), 128 (2.9), 113 (3.6), 100 (17.8), 91 (10.7), 82 (5), 70 (26.4), 56 (10). Anal. Calcd. for C₁₇H₂₅N₅O₂ (331.4): C, 61.61; H, 7.60; N, 21.13; O, 9.66. Found C, 61.82; H, 7.52; N, 21.22.

3.2. Docking Study

The chemical structures of the compounds were drawn in the Hyperchem 8 and minimized using the AM1 method. Log P for the synthesized compounds and fluconazole were calculated using HyperChem 8. The X-ray crystallographic structure of cytochrome P450 14 α -demethylase (PDB deposited code: 1EA1) was retrieved from the protein data bank and was optimized using the Gromacs package [26]. Cognate ligand fluconazole (TPF) was removed from the initial receptor structure and all docking procedures were performed on chain A of 14 α -demethylase. All the pre-processing steps for receptor crystallographic structure and partial charge calculations were performed via the AutoDock Tools 1.5.4 program (ADT) (The scripps research institute, La Jolla, California, USA) [27]. To verify the reproducibility of docking calculations, the cognate ligand was redocked, and the final docked conformations resulted in 1–1.5 Å root-mean-square deviation. The Lamarckian genetic algorithm (LGA) was applied to model the interaction between ligands and 14 α -demethylase active site. For the Lamarckian genetic algorithm: 27,000 maximum generations; a gene mutation rate of 0.02 and; a crossover rate of 0.8 were used. The grid box size was set to 60 × 60 × 60 points in x, y and z directions, respectively. The box was centered based on the cognate ligand with a spacing of 0.375 Å. Cluster analysis was performed on the docked results using an RMSD (Root Mean Square Deviation) tolerance of 2 Å. All the compounds, as well as fluconazole, were docked according to the aforementioned parameters. Interactions were identified using the LigPlot software and the figures were prepared using VMD 1.9.1.

3.3. Biological Activity

Antifungal activities of the synthesized compounds were evaluated against standard and clinical species of the yeasts and filamentous fungi. The compounds were dissolved in DMSO at the concentration of 200 mg/mL. Afterward, compounds were diluted in broth media to obtain final concentrations. Minimal inhibitory concentrations (MIC) of the synthesized compounds were determined by the broth microdilution method as recommended by CLSI (Clinical & Laboratory

Standards Institute), with some modifications [28,29]. Briefly, the serial dilutions of compounds **5a–j** (625 to 0.5 µg/mL) were prepared in 96-well plates using RPMI 1640 media. Stock inoculums were prepared by suspending three colonies of the tested yeasts in 5 mL of sterile 0.9% NaCl, and adjusting the turbidity of the inoculums to 0.5 at a 530 nm wavelength to yield a stock suspension of $1\text{--}5 \times 10^6$ cells/mL. For filamentous fungi (*Aspergillus* and dermatophytes), conidia were recovered from 2–7 days old cultures grown on potato dextrose agar by a wetting loop with Tween 20. The collected conidia were transferred in sterile saline and their turbidity was adjusted in OD = 0.09–0.11 ($0.4\text{--}5 \times 10^6$ conidia/mL). Working suspensions were prepared by making a 1/50 and 1/1000 dilution with RPMI of the stock suspension for filamentous fungi and yeasts, respectively. After addition of 0.1 mL of the inoculums to the wells, the trays were incubated at 30 °C for 24–48 h in a humid atmosphere. 200 µL of the uninoculated medium was incubated as a sterility control (blank). In addition, growth controls [medium with inoculums and 5% (*v/v*) DMSO (maximum DMSO concentration) without the synthetic compounds] were also incubated. MICs were visually determined and defined as the lowest concentration of the compounds that produced ≥ 50 growth inhibitions. Each experiment was performed in triplicate and the mean MICs was reported as MIC₅₀.

4. Conclusions

Here two series of novel fluconazole-derivatives containing nitrotriazole or 2-(piperazin-1-yl) ethanol moieties were synthesized. The antifungal activities of all compounds were evaluated against several standard and clinically isolated yeasts. MICs of the synthesized compounds were obtained and compared with fluconazole. All the synthesized derivatives except **5i**, **5j** and **5h** exhibited moderate to high in vitro antifungal activities. Compound **5b** was the most active antifungal agents against all fungal strains except *Aspergillus* sp; which is comparable to fluconazole. Compounds **5b** and **5g** with two chlorine atoms in their structure showed maximum antifungal activity.

Furthermore, the compounds containing 2-(1-piperazinyl) ethanol moiety were able to form ester derivatives on the hydroxyl group in ethanol moiety; therefore, these compounds can be considerably prolonged by the preparation of fatty acid esters for a long duration.

Acknowledgments: The authors would like to thank Shiraz University of Medical Sciences for its kind contribution in providing the needed funding and facilities for this work.

Author Contributions: H.S. contributed to management of synthetic part and preparation of the manuscript; Z.R. contributed in Designing the target compound and supervising all part of the work and approval of final article; S.K. contributed in supervising the synthesis steps; K.Z and K.P. contributed to management of antifungal experiments; K.H. and N.J. performed the experiments; E.-F.M. contributed in computational studies and writing some part of manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Spitzer, M.; Griffiths, E.; Blakely, K.M.; Wildenhain, J.; Ejim, L.; Rossi, L.; De Pascale, G.; Curak, J.; Brown, E.; Tyers, M. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. *Mol. Syst. Biol.* **2011**, *7*, 499–512.
2. Armstrong-James, D.; Meintjes, G.; Brown, G.D. A neglected epidemic: Fungal infections in HIV/AIDS. *Trends Microbiol.* **2014**, *22*, 120–127.
3. Salari, S.; Khosravi, A.; Mousavi, S.; Nikbakht-Brojeni, G. Mechanisms of resistance to fluconazole in candida albicans clinical isolates from iranian hiv-infected patients with oropharyngeal candidiasis. *J. Méd. Mycol.* **2016**, *26*, 35–41.
4. Batzlaff, C.M.; Limper, A.H. When to consider the possibility of a fungal infection: An overview of clinical diagnosis and laboratory approaches. *Clin. Chest Med.* **2017**, doi:10.1016/j.ccm.2017.04.002.
5. Lamb, D.C.; Kelly, D.E.; Venkateswarlu, K.; Manning, N.J.; Bligh, H.F.J.; Schunck, W.H.; Kelly, S.L. Generation of a complete, soluble and catalytically active sterol 14 α -demethylase-reductase complex. *Biochemistry* **1999**, *38*, 8733–8738.

6. Bartoli, J.; Turmo, E.; Algueró, M.; Boncompte, E.; Vericat, M.L.; Conte, L.; Ramis, J.; Merlos, M.; García-Rafanell, J.; Forn, J. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. *J. Med. Chem.* **1998**, *41*, 1869–1882.
7. Upadhayaya, R.S.; Jain, S.; Sinha, N.; Kishore, N.; Chandra, R.; Arora, S.K. Synthesis of novel substituted tetrazoles having antifungal activity. *Eur. J. Med. Chem.* **2004**, *39*, 579–592.
8. Lebouvier, N.; Giraud, F.; Corbin, T.; Na, Y.M.; Le Baut, G.; Marchand, P.; Le Borgne, M. Efficient microwave-assisted synthesis of 1-(1H-indol-1-yl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. *Tetrahedron Lett.* **2006**, *47*, 6479–6483.
9. Lebouvier, N.; Pagniez, F.; Duflos, M.; Le Pape, P.; Na, Y.M.; Le Baut, G.; Le Borgne, M. Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3686–3689.
10. Xu, Y.; Sheng, C.; Wang, W.; Che, X.; Cao, Y.; Dong, G.; Wang, S.; Ji, H.; Miao, Z.; Yao, J. Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2942–2945.
11. Che, X.; Sheng, C.; Wang, W.; Cao, Y.; Xu, Y.; Ji, H.; Dong, G.; Miao, Z.; Yao, J.; Zhang, W. New azoles with potent antifungal activity: Design, synthesis and molecular docking. *Eur. J. Med. Chem.* **2009**, *44*, 4218–4226.
12. Yu, S.; Wang, L.; Wang, Y.; Song, Y.; Cao, Y.; Jiang, Y.; Sun, Q.; Wu, Q. Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives containing the 1,2,3-triazole group. *RSC Adv.* **2013**, *3*, 13486–13490.
13. Hashemi, S.M.; Badali, H.; Faramarzi, M.A.; Samadi, N.; Afsarian, M.H.; Irannejad, H.; Emami, S. Novel triazole alcohol antifungals derived from fluconazole: Design, synthesis, and biological activity. *Mol. Divers.* **2014**, *19*, 15–27.
14. Kathiravan, M.K.; Salake, A.B.; Chothe, A.S.; Dudhe, P.B.; Watode, R.P.; Mukta, M.S.; Gadhwe, S. The biology and chemistry of antifungal agents: A review. *Bioorg. Med. Chem.* **2012**, *20*, 5678–5698.
15. Yehye, W.A.; Abdul Rahman, N.; Saad, O.; Ariffin, A.; Abd Hamid, S.B.; Alhadi, A.A.; Kadir, F.A.; Yaeghoobi, M.; Matlob, A.A. Rational design and synthesis of new, high efficiency, multipotent schiff base-1, 2, 4-triazole antioxidants bearing butylated hydroxytoluene moieties. *Molecules* **2016**, *21*, 847.
16. Jana, S.; Iram, S.; Thomas, J.; Hayat, M.Q.; Pannecouque, C.; Dehaen, W. Application of the triazolization reaction to afford dihydroartemisinin derivatives with anti-HIV activity. *Molecules* **2017**, *22*, 303.
17. Giofrè, S.V.; Romeo, R.; Carnovale, C.; Mancuso, R.; Cirmi, S.; Navarra, M.; Garozzo, A.; Chiacchio, M.A. Synthesis and biological properties of 5-(1H-1,2,3-triazol-4-yl)isoxazolidines: A new class of c-nucleosides. *Molecules* **2015**, *20*, 5260–5275.
18. Iannazzo, D.; Pistone, A.; Ziccarelli, I.; Espro, C.; Galvagno, S.; Giofrè, S.V.; Romeo, R.; Cicero, N.; Bua, G.D.; Lanza, G. Removal of heavy metal ions from wastewaters using dendrimer-functionalized multi-walled carbon nanotubes. *Environ. Sci. Pollut. Res.* **2017**, *17*, 14735–14747.
19. Iannazzo, D.; Pistone, A.; Visco, A.; Galtieri, G.; Giofrè, S.V.; Romeo, R.; Romeo, G.; Cappello, S.; Bonsignore, M.; Denaro, R. 1,2,3-triazole/mwcnt conjugates as filler for gelcoat nanocomposites: New active antibiofouling coatings for marine application. *Mater. Res. Express* **2015**, *2*, 115001.
20. Mital, A. Synthetic nitroimidazoles: Biological activities and mutagenicity relationships. *Sci. Pharm.* **2009**, *77*, 497–520.
21. Sun, Q.Y.; Xu, J.M.; Cao, Y.B.; Zhang, W.N.; Wu, Q.Y.; Zhang, D.Z.; Zhang, J.; Zhao, H.Q.; Jiang, Y.Y. Synthesis of novel triazole derivatives as inhibitors of cytochrome p450 14 α -demethylase (CYP51). *Eur. J. Med. Chem.* **2007**, *42*, 1226–1233.
22. Chai, X.; Zhang, J.; Hu, H.; Yu, S.; Sun, Q.; Dan, Z.; Jiang, Y.; Wu, Q. Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome p450 14 α -demethylase. *Eur. J. Med. Chem.* **2009**, *44*, 1913–1920.
23. Liang, Z.; Xu, H.; Tian, Y.; Guo, M.; Su, X.; Guo, C. Design, synthesis and antifungal activity of novel benzofuran-triazole hybrids. *Molecules* **2016**, *21*, 732.
24. Nimbalkar, U.D.; Tupe, S.G.; Seijas Vazquez, J.A.; Khan, F.A.; Sangshetti, J.N.; Nikalje, A.P.G. Ultrasound- and molecular sieves-assisted synthesis, molecular docking and antifungal evaluation of 5-(4-(Benzyloxy)-substituted phenyl)-3-((phenylamino) methyl)-1,3,4-oxadiazole-2(3H)-thiones. *Molecules* **2016**, *21*, 484.

25. Borate, H.B.; Maujan, S.R.; Sawargave, S.P.; Chandavarkar, M.A.; Vaiude, S.R.; Joshi, V.A.; Wakharkar, R.D.; Iyer, R.; Kelkar, R.G.; Chavan, S.P. Fluconazole analogues containing 2H-1,4-benzothiazin-3(4H)-one or 2H-1,4-benzoxazin-3(4H)-one moieties, a novel class of anti-candida agents. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 722–725.
26. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A.E.; Berendsen, H.J. Gromacs: Fast, flexible, and free. *J. Comput. Chem.* **2005**, *26*, 1701–1718.
27. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and autodocktools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791.
28. Clinical and Laboratory Standards Institute. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi*, 2nd ed.; Approved Standard Clsi Document M38-A2; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008.
29. Clinical and Laboratory Standards Institute. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*, 3rd ed.; Approved Standard Clsi Document M27-A3; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008.

Sample Availability: Not Available.



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).